Cargando…

Weaker Effects of the Fourth Dose of BNT162b2 SARS-CoV-2 Vaccine on the Elderly Human Population

The vaccines presently available are less effective in older people due to senescence of their immune systems. We measured the antibody responses of 42 adults living in nursing homes after the third and the fourth doses of an mRNA vaccine and found that the strain (BA.2 and BA.2.75: from 64 to 128,...

Descripción completa

Detalles Bibliográficos
Autores principales:	Dimeglio, Chloé, Da-Silva, Isabelle, Porcheron, Marion, Panero, Marie-Pierre, Staes, Laetitia, Trémeaux, Pauline, Villars, Hélène, Izopet, Jacques
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2023
Materias:	Brief Report
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10301649/ https://www.ncbi.nlm.nih.gov/pubmed/37376484 http://dx.doi.org/10.3390/vaccines11061095

Ejemplares similares

Post-vaccination SARS-CoV-2 antibody kinetics and protection duration against Omicron in elderly population
por: Dimeglio, Chloé, et al.
Publicado: (2022)

Influence of immune escape and nasopharyngeal virus load on the spread of SARS-CoV-2 Omicron variant
por: Migueres, Marion, et al.
Publicado: (2022)

Decreased Efficiency of Neutralizing Antibodies from Previously Infected or Vaccinated Individuals against the B.1.617.2 (Delta) SARS-CoV-2 Variant
por: Dimeglio, Chloé, et al.
Publicado: (2022)

Evaluation of Three Quantitative Anti-SARS-CoV-2 Antibody Immunoassays
por: Chapuy-Regaud, Sabine, et al.
Publicado: (2021)

One year later: SARS-CoV-2 immune response and vaccination of healthcare workers post-infection
por: Dimeglio, Chloé, et al.
Publicado: (2021)

Influence of vaccination and prior immunity on the dynamics of Omicron BA.1 and BA.2 sub-variants
por: Dimeglio, Chloé, et al.
Publicado: (2022)

Antibody Titers and Protection against Omicron (BA.1 and BA.2) SARS-CoV-2 Infection
por: Dimeglio, Chloé, et al.
Publicado: (2022)

Influence of the Delta Variant and Vaccination on the SARS-CoV-2 Viral Load
por: Migueres, Marion, et al.
Publicado: (2022)

Whole‐genome sequencing of SARS‐CoV‐2: Comparison of target capture and amplicon single molecule real‐time sequencing protocols
por: Nicot, Florence, et al.
Publicado: (2022)

Protection by a Fourth Dose of BNT162b2 against Omicron in Israel
por: Bar-On, Yinon M., et al.
Publicado: (2022)

Boosting capacity of a fourth dose BNT162b2 in cancer patients
por: Debie, Yana, et al.
Publicado: (2023)

Influence of SARS-CoV-2 Variant B.1.1.7, Vaccination, and Public Health Measures on the Spread of SARS-CoV-2
por: Dimeglio, Chloé, et al.
Publicado: (2021)

Fourth BNT162b2 vaccination neutralization of omicron infection after heart transplantation
por: Peled, Yael, et al.
Publicado: (2022)

Will the latest wave of the COVID‐19 pandemic be an ecological disaster? There is an urgent need to replace plastic by ecologically virtuous materials
por: Mansuy, Jean‐Michel, et al.
Publicado: (2022)

Comparative effects of mRNA vaccine booster and natural Omicron infection on the neutralizing antibody response
por: Dimeglio, Chloé, et al.
Publicado: (2022)

Six-Month Follow-up after a Fourth BNT162b2 Vaccine Dose
por: Canetti, Michal, et al.
Publicado: (2022)

Children are protected against SARS-CoV-2 infection
por: Dimeglio, Chloé, et al.
Publicado: (2020)

Fourth Dose of BNT162b2 mRNA Covid-19 Vaccine in a Nationwide Setting
por: Magen, Ori, et al.
Publicado: (2022)

The Humoral Response of Patients With Cancer to Breakthrough COVID-19 Infection or the Fourth BNT162b2 Vaccine Dose
por: Cohen, Idan, et al.
Publicado: (2023)

Omicron Wave SARS-CoV-2 Diagnosis: Evaluation of Saliva, Anterior Nasal, and Nasopharyngeal Swab Samples
por: Migueres, Marion, et al.
Publicado: (2022)

Humoral and T-Cell Response before and after a Fourth BNT162b2 Vaccine Dose in Adults ≥60 Years
por: Bar-Haim, Erez, et al.
Publicado: (2022)

Antibody response to third and fourth BNT162b2 mRNA booster vaccinations in healthcare workers in Tokyo, Japan
por: Sanada, Takahiro, et al.
Publicado: (2023)

Blunted humoral immune response to the fourth dose of BNT162b2 COVID-19 vaccine in patients undergoing hemodialysis
por: Kanai, Daisuke, et al.
Publicado: (2023)

Influence of a Heterologous (ChAdOx1-nCoV-19/BNT162b2) or Homologous (BNT162b2/BNT162b2) Vaccination Regimen on the Antibody and T Cell Response to a Third Vaccination with BNT162b2
por: Reiter, Rieke, et al.
Publicado: (2022)

Quantifying the impact of public health protection measures on the spread of SARS-CoV-2
por: Dimeglio, Chloé, et al.
Publicado: (2021)

Antibody Titers After a Third and Fourth SARS-CoV-2 BNT162b2 Vaccine Dose in Older Adults
por: Eliakim-Raz, Noa, et al.
Publicado: (2022)

Immunogenicity and SARS-CoV-2 Infection following the Fourth BNT162b2 Booster Dose among Health Care Workers
por: Shachor-Meyouhas, Yael, et al.
Publicado: (2023)

Duration of humoral response to the third dose of BNT162b2 vaccine in patients with solid cancer: Is fourth dose urgently needed?
por: Di Noia, Vincenzo, et al.
Publicado: (2022)

Humoral and cellular response before and after the fourth BNT162b2 vaccine dose in patients with solid tumors on active treatment
por: Lasagna, A., et al.
Publicado: (2022)

Prediction of SARS-CoV-2 Variant Lineages Using the S1-Encoding Region Sequence Obtained by PacBio Single-Molecule Real-Time Sequencing
por: Lhomme, Sébastien, et al.
Publicado: (2021)

Antibody titers and breakthrough infections with Omicron SARS-CoV-2
por: Dimeglio, Chloé, et al.
Publicado: (2022)

Antibody titers and protection against a SARS-CoV-2 infection
por: Dimeglio, Chloé, et al.
Publicado: (2022)

Humoral Response and SARS-CoV-2 Infection Risk following the Third and Fourth Doses of the BNT162b2 Vaccine in Dialysis Patients
por: Einbinder, Yael, et al.
Publicado: (2022)

Testing individual and pooled saliva samples for sars-cov-2 nucleic acid: a prospective study
por: Migueres, Marion, et al.
Publicado: (2021)

Evaluation of the Aptima™ transcription-mediated amplification assay (Hologic®) for detecting SARS-CoV-2 in clinical specimens
por: Trémeaux, Pauline, et al.
Publicado: (2020)

COVID-19 vaccine uptake among healthcare workers in the fourth country to authorize BNT162b2 during the first month of rollout
por: Barry, Mazin, et al.
Publicado: (2021)

Immunogenicity and efficacy of fourth BNT162b2 and mRNA1273 COVID-19 vaccine doses; three months follow-up
por: Canetti, Michal, et al.
Publicado: (2022)

Safety of the fourth COVID-19 BNT162b2 mRNA (second booster) vaccine: a prospective and retrospective cohort study
por: Yechezkel, Matan, et al.
Publicado: (2023)

Eight-Month Follow-up After the Third Dose of BNT162b2 Vaccine in Healthcare Workers: The Question of a Fourth Dose
por: Lim, Sung Hee, et al.
Publicado: (2023)

Response Rate of the Third and Fourth Doses of the BNT162b2 Vaccine Administered to Cancer Patients Undergoing Active Anti-Neoplastic Treatments
por: Agbarya, Abed, et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_lqdeojkobhg1pdcbu7ctosevt8